联合应用胸腺肽α1治疗老年重症肺炎的疗效观察  

Effect of combination with the thymosin alpha 1 in elderly severe pneumonia

作　　者：陈海英[1] 张键[1] 

机构地区：[1]常德市第一人民医院老年病科,湖南常德415000

出　　处：《现代医学》2013年第4期255-258,共4页Modern Medical Journal

摘　　要：目的:探讨联合应用胸腺肽α1治疗老年重症肺炎的临床疗效。方法:将58例老年重症肺炎患者随机分为联合免疫增强治疗组和一般治疗组,两组均予以常规治疗。联合免疫增强治疗组在一般治疗组治疗基础上加用胸腺肽α1 1.6 mg皮下注射,1次.d-1,疗程1周。观察两组患者细胞免疫功能水平,血清C-反应蛋白、血清降钙素原水平及临床疗效。结果:治疗后联合免疫增强治疗组CD3+、CD4+、CD4+/CD8+水平较一般治疗组明显改善[分别为(61.1±5.4)%与(56.5±5.2)%、(43.0±4.1)%与(37.5±3.3)%、(1.7±0.7)与(1.3±0.6),P<0.05],C-反应蛋白和降钙素原水平较一般治疗组明显下降[分别为(39.5±9.9)mg.L-1与(51.5±13.2)mg.L-1、(0.2±0.1)μg.L-1与(0.5±0.2)μg.L-1,P<0.05],临床有效率明显高于一般治疗组(分别为86.2%和65.5%,P<0.05)。结论:胸腺肽α1能改善老年重症肺炎患者的免疫功能,用于治疗老年重症肺炎效果明显。Objective： To study the effect of combination with the thymosin alpha 1 in elderly severe pneumonia patients. Methods： Fifty-eight elderly patients with severe pneumonia were divided into two groups randomly： combined immunization therapy group and general therapy group. Both were treated with routine method, but in the combined immunization therapy group, the patients received 1.6 mg of thymosin alpha 1 through subcutaneous injection once a day for 1 week. Cellular immune function, serum C-reactive protein（ C RP）, procalcitonin（PCT） and therapeutic effect were observed. Results： In combined immunization therapy group CD3 ＋ ,CD4＋ ,CD4＋/CD8 ＋ were improved significantly and better than general therapy group [ （ 61.1 ± 5.4） % vs （ 56.5 ± 5.2 ） %, （43.0± 4.1 ） % vs （ 37.5 ± 3.3 ） %, （ 1.7 ± 0.7 ） vs （ 1.3 ± 0.6 ）, P 〈 0.05 ], C- reactive protein and procalcitonin were obviously decreased [（39.5 ±9.9） mg·L^-1 vs （51.5 ±13.2） mg ·L^-1,（0.2±0. 1 ）μg·L^-1 vs （0.5± 0.2） μg·L^-1, P 〈 0.05 ], the clinical effective rate was higher （ 86.2% vs 65.5% , P 〈 0.05 ）. Conclusion：Thymosin alpha 1 is great benefit to immune function in elderly severe pneumonia patients. The effect of combination with thymosin alpha 1 therapy in elderly severe pneumonia patients is obvious.

关 键 词：胸腺肽Α1 重症肺炎 老年 

分 类 号：R563.1[医药卫生—呼吸系统]